6 completed, 4 active not recruiting, 1 recruiting, 1 withdrawn. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 4, Completed 4, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
Follow Recurrent Lymphoplasmacytic Lymphoma: new trials by email Literature Review of Recurrent Lymphoplasmacytic Lymphoma trials Research Report on Recurrent Lymphoplasmacytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2013-09-24 | 2026-05-13 |
| Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Temsirolimus - AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 110 | 2010-04-15 | 2019-10-16 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 73 | 2008-06-25 | 2019-12-27 |
Lymphoma, B-Cell, Marginal Zone (12) · Lymphoma, Follicular (12) · Lymphoma, Mantle-Cell (9) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, B-Cell (6) · Lymphoma, Large B-Cell, Diffuse (6) · Waldenstrom Macroglobulinemia (6) · Burkitt Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3) · Hodgkin Disease (2) · Leukemia, Hairy Cell (2) · Leukemia, Prolymphocytic, B-Cell (2) · Myelodysplastic Syndromes (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Hematologic Diseases (11) · Lymphoma (11) · Lymphoma, Non-Hodgkin (9) · Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Chronic Disease (7) · Disease Attributes (7) · Hemorrhagic Disorders (7)
Lenalidomide (5) · ibrutinib (4) · Cyclophosphamide (3) · fludarabine phosphate (3) · Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · pembrolizumab (2) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Cyclosporins (1) · Etoposide (1) · Immunotherapy, Adoptive (1)
City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · David Bond, MD (1) · Joseph Tuscano (1) · Kami Maddocks (1) · Yazeed Sawalha (1)
United States (11) · Canada (1)
Alexey Danilov (1) · Beth A Christian (1) · David Bond, MD (1) · Jithma P. Abeykoon, MD (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1) · Mazyar Shadman (1) · Rachel Salit (1) · Sonali Smith (1) · Tanya Siddiqi (1) · Wei Ding (1) · Yazeed Sawalha, MD (1)
PMID 28424162, PMID 34320785, PMID 34492703, PMID 34515338, PMID 36631449
P30CA016058 (2), K24CA201524 (1), N01CM00071 (1), N01CM62201 (1), P30CA014599 (1), P30CA015704 (1), P30CA033572 (1), P30CA069533 (1), P30CA093373 (1), P50CA097274 (1), U01CA076576 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186705 (1), UM1CA186712 (1)